

Kratom (*Mitragyna speciosa*): User demographics, use patterns, and its role in the opioid epidemic

Drug and Alcohol Dependence

208, 107849

DOI: [10.1016/j.drugalcdep.2020.107849](https://doi.org/10.1016/j.drugalcdep.2020.107849)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pharmacology of Herbal Sexual Enhancers: A Review of Psychiatric and Neurological Adverse Effects. <i>Pharmaceuticals</i> , 2020, 13, 309.	1.7	11
2	Lyophilized Kratom Tea as a Therapeutic Option for Opioid Dependence. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108310.	1.6	40
3	Can Kratom (<i>Mitragyna speciosa</i>) Alleviate COVID-19 Pain? A Case Study. <i>Frontiers in Psychiatry</i> , 2020, 11, 594816.	1.3	11
4	Effects of kratom (<i>Mitragyna speciosa</i> Korth.) in reducing risk-behaviors among a small sample of HIV positive opiate users in Malaysia. <i>Journal of Ethnicity in Substance Abuse</i> , 2022, 21, 1285-1295.	0.6	2
5	Evaluation of the Mitragynine Content, Levels of Toxic Metals and the Presence of Microbes in Kratom Products Purchased in the Western Suburbs of Chicago. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5512.	1.2	25
6	Kratom instrumentalization for severe pain self-treatment resulting in addiction – A case report of acute and chronic subjective effects. <i>Heliyon</i> , 2020, 6, e04507.	1.4	25
7	Evaluation of the rewarding effects of mitragynine and 7 α -hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108235.	1.6	19
8	Current and Future Potential Impact of COVID-19 on Kratom (<i>Mitragyna speciosa</i> Korth.) Supply and Use. <i>Frontiers in Psychiatry</i> , 2020, 11, 574483.	1.3	5
9	Global strategy for New Psychoactive Substances: an update. <i>Current Opinion in Psychiatry</i> , 2020, 33, 295-300.	3.1	8
10	Lipid profile of regular kratom (<i>Mitragyna speciosa</i> Korth.) users in the community setting. <i>PLoS ONE</i> , 2020, 15, e0234639.	1.1	12
11	Prevalence and description of kratom (<i>Mitragyna speciosa</i>) use in the United States: a cross-sectional study. <i>Addiction</i> , 2021, 116, 176-181.	1.7	81
12	Kratom use in the United States: Response to Grundmann <i>et al</i> .. <i>Addiction</i> , 2021, 116, 203-204.	1.7	3
13	Kratom use in the United States: a diverse and complex profile. <i>Addiction</i> , 2021, 116, 202-203.	1.7	14
14	Liver injury associated with kratom, a popular opioid-like product: Experience from the U.S. drug induced liver injury network and a review of the literature. <i>Drug and Alcohol Dependence</i> , 2021, 218, 108426.	1.6	19
15	Exploring the use of Kratom (<i>Mitragyna speciosa</i>) via the YouTube data tool: A novel netnographic analysis. <i>Emerging Trends in Drugs, Addictions, and Health</i> , 2021, 1, 100007.	0.5	10
16	Kratom (<i>Mitragyna speciosa</i> Korth.) an overlooked medicinal plant in Malaysia. <i>Journal of Substance Use</i> , 2022, 27, 1-6.	0.3	8
17	Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review. <i>Journal of Perinatology</i> , 2021, 41, 1236-1243.	0.9	13
18	Report of ventricular fibrillation in a 44-year-old man using kratom. <i>BMJ Case Reports</i> , 2021, 14, e237837.	0.2	12

#	ARTICLE	IF	CITATIONS
19	Assessing the quality of information provided on websites selling Kratom (<i>Mitragyna speciosa</i>) to consumers in Canada. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 23.	1.0	4
20	Brief correspondence: kratom. <i>Journal of Perinatology</i> , 2021, 41, 1511-1511.	0.9	1
21	When an obscurity becomes trend: social-media descriptions of tianeptine use and associated atypical drug use. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 455-466.	1.1	24
22	Influence of G protein-biased agonists of μ -opioid receptor on addiction-related behaviors. <i>Pharmacological Reports</i> , 2021, 73, 1033-1051.	1.5	10
23	Kratom: A systematic review of toxicological issues. <i>Wiley Interdisciplinary Reviews Forensic Science</i> , 2022, 4, .	1.2	7
24	The Use of Kratom (<i>Mitragyna speciosa</i> Korth.) Among People Who Co-use Heroin and Methamphetamine in Malaysia. <i>Journal of Addiction Medicine</i> , 2021, Publish Ahead of Print, .	1.4	15
25	Kratom use for depression/anxiety self-management: challenges during the COVID-19 pandemic – A case report. <i>Heliyon</i> , 2021, 7, e07039.	1.4	13
26	A Case Report of Kratom-Induced Psychosis. <i>Cureus</i> , 2021, 13, e16073.	0.2	3
27	Site selective C ¹⁴ H functionalization of <i>Mitragyna</i> alkaloids reveals a molecular switch for tuning opioid receptor signaling efficacy. <i>Nature Communications</i> , 2021, 12, 3858.	5.8	25
28	Kratom exposures among older adults reported to U.S. poison centers, 2014–2019. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 2176-2184.	1.3	12
29	Kratom use disorder: a primer for primary care physicians. <i>Journal of Addictive Diseases</i> , 2021, , 1-11.	0.8	2
30	A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans. <i>Human Psychopharmacology</i> , 2022, 37, e2805.	0.7	19
31	Pentylentetrazol-like stimulus is not produced following naloxone-precipitated mitragynine withdrawal in rats. <i>Psychopharmacology</i> , 2021, 238, 3183-3191.	1.5	6
32	Prevalence of Kratom Use and Co-Occurring Substance Use Disorders in the United States. <i>primary care companion for CNS disorders, The</i> , 2021, 23, .	0.2	8
33	Kratom Use Within the Context of the Evolving Opioid Crisis and the COVID-19 Pandemic in the United States. <i>Frontiers in Pharmacology</i> , 2021, 12, 729220.	1.6	13
34	Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use. <i>Drug and Alcohol Dependence</i> , 2021, 226, 108879.	1.6	39
35	Application and Clinical Value of Definitive Drug Monitoring in Pain Management and Addiction Medicine. <i>Pain Medicine</i> , 2022, 23, 821-833.	0.9	5
36	Characterization of urinary protein profile in regular kratom (<i>Mitragyna speciosa</i> korth.) users in Malaysia. <i>Journal of Addictive Diseases</i> , 2022, 40, 235-246.	0.8	3

#	ARTICLE	IF	CITATIONS
37	The effect of mitragynine on extracellular activity of brain dopamine and its metabolites. <i>Brain Research Bulletin</i> , 2022, 178, 1-8.	1.4	2
38	Clinical Pharmacology of the Dietary Supplement Kratom (<i>Mitragyna speciosa</i>). <i>Journal of Clinical Pharmacology</i> , 2022, 62, 577-593.	1.0	9
39	Associations of Lifetime Nonmedical Opioid, Methamphetamine, and Kratom Use within a Nationally Representative US Sample. <i>Journal of Psychoactive Drugs</i> , 2021, , 1-11.	1.0	7
40	Kratom Abuse Potential 2021: An Updated Eight Factor Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 775073.	1.6	15
41	Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder. <i>Journal of the Neurological Sciences</i> , 2022, 432, 120094.	0.3	6
42	We Need Better Estimates of Kratom Use Prevalence. <i>American Journal of Preventive Medicine</i> , 2022, 62, 132-133.	1.6	9
43	Mini review: Potential therapeutic values of mitragynine as an opioid substitution therapy. <i>Neuroscience Letters</i> , 2022, 773, 136500.	1.0	7
44	Endogenous opiates and behavior: 2020. <i>Peptides</i> , 2022, 151, 170752.	1.2	12
45	Kratom Use Is Underestimated, but Prevalence Still Appears to Be Low. <i>American Journal of Preventive Medicine</i> , 2022, 62, 133-134.	1.6	2
46	In vitro and in vivo pharmacology of kratom. <i>Advances in Pharmacology</i> , 2022, 93, 35-76.	1.2	13
47	Assessment of Kratom Use Disorder and Withdrawal Among an Online Convenience Sample of US Adults. <i>Journal of Addiction Medicine</i> , 2022, 16, 666-670.	1.4	19
48	How essential is kratom availability and use during COVID-19? Use pattern analysis based on survey and social media data. <i>Substance Abuse</i> , 2022, 43, 865-877.	1.1	7
49	Understanding Kratom Use: A Guide for Healthcare Providers. <i>Frontiers in Pharmacology</i> , 2022, 13, 801855.	1.6	30
50	Searching for a Signal: Self-Reported Kratom Dose-Effect Relationships Among a Sample of US Adults With Regular Kratom Use Histories. <i>Frontiers in Pharmacology</i> , 2022, 13, 765917.	1.6	19
51	Exploring the self-reported motivations of kratom (<i>Mitragyna speciosa</i> Korth.) use: a cross-sectional investigation. <i>American Journal of Drug and Alcohol Abuse</i> , 2022, 48, 433-444.	1.1	15
52	Kratom Use in the US: Both a Regional Phenomenon and a White Middle-Class Phenomenon? Evidence From NSDUH 2019 and an Online Convenience Sample. <i>Frontiers in Pharmacology</i> , 2021, 12, 789075.	1.6	12
53	The Identification of Prenatal Exposure to Mitragynine Using Umbilical Cord Tissue. <i>American Journal of Analytical Chemistry</i> , 2022, 13, 162-174.	0.3	1
54	Health Effects Associated With Kratom (<i>Mitragyna speciosa</i>) and Polysubstance Use: A Narrative Review. <i>Substance Abuse: Research and Treatment</i> , 2022, 16, 117822182210958.	0.5	9

#	ARTICLE	IF	CITATIONS
56	Acute, Sublethal, and Developmental Toxicity of Kratom (<i>Mitragyna speciosa</i> Korth.) Leaf Preparations on <i>Caenorhabditis elegans</i> as an Invertebrate Model for Human Exposure. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6294.	1.2	3
57	Need for Clarity and Context in Case Reports on Kratom Use, Assessment, and Intervention. <i>Substance Abuse</i> , 2022, 43, 1221-1224.	1.1	8
58	Kratom: History, pharmacology, current user trends, adverse health effects and potential benefits. <i>Disease-a-Month</i> , 2023, 69, 101442.	0.4	7
59	Kratom use as more than a "self-treatment". <i>American Journal of Drug and Alcohol Abuse</i> , 2022, 48, 684-694.	1.1	20
60	Kratom: Substance of Abuse or Therapeutic Plant?. <i>Psychiatric Clinics of North America</i> , 2022, 45, 415-430.	0.7	2
61	Public Health Implications and Possible Sources of Lead (Pb) as a Contaminant of Poorly Regulated Kratom Products in the United States. <i>Toxics</i> , 2022, 10, 398.	1.6	4
62	Kratom as a novel cause of photodistributed hyperpigmentation. <i>JAAD Case Reports</i> , 2022, 28, 145-148.	0.4	2
63	Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature. <i>American Journal of Drug and Alcohol Abuse</i> , 2022, 48, 509-528.	1.1	6
64	Narrative Review of Kratom, an Emerging Psychoactive Substance With Perianesthetic Implications. <i>Anesthesia and Analgesia</i> , 2022, 135, 1180-1188.	1.1	3
65	Kratom use categories and their associations with co-occurring substance use and mental health disorder symptoms during the COVID-19 pandemic. <i>Drug and Alcohol Dependence</i> , 2022, 239, 109605.	1.6	6
66	Qualitative content analysis of public responses to an FDA inquiry on the impact of scheduling changes to kratom. <i>International Journal of Drug Policy</i> , 2022, 108, 103817.	1.6	6
67	For Better or Worse: Self-reported Changes in Kratom and Other Substance Use as a Result of the COVID-19 Pandemic. <i>Substance Abuse: Research and Treatment</i> , 2022, 16, 117822182211239.	0.5	1
68	Hepatotoxicity due to herbal dietary supplements: Past, present and the future. <i>Food and Chemical Toxicology</i> , 2022, 169, 113445.	1.8	9
69	Kratom-Associated Mixed Cholestatic-Hepatocellular Liver Injury in a Patient With Long COVID: A case Report. <i>Clinical Medicine Insights: Case Reports</i> , 2022, 15, 117954762211328.	0.3	1
70	This Month in JAAD Case Reports: January 2023 Kratom Hyperpigmentation. <i>Journal of the American Academy of Dermatology</i> , 2022, , .	0.6	0
71	Polysubstance use profiles among US adults using Kratom (<i>Mitragyna speciosa</i>): A latent class analysis using The National Survey on Drug Use and Health (NSDUH). <i>American Journal on Addictions</i> , 0, , .	1.3	0
72	Respiratory effects of oral mitragynine and oxycodone in a rodent model. <i>Psychopharmacology</i> , 2022, 239, 3793-3804.	1.5	6
73	Kava (<i>Piper methysticum</i>) in the United States: the quiet rise of a substance with often subtle effects. <i>American Journal of Drug and Alcohol Abuse</i> , 2023, 49, 85-96.	1.1	3

#	ARTICLE	IF	CITATIONS
74	Analysis of heavy metals content in commercially available kratom products in Richmond, Virginia. Forensic Chemistry, 2023, 33, 100474.	1.7	1
75	Kratom withdrawal: Discussions and conclusions of a scientific expert forum. , 2023, 7, 100142.		1
76	Kratom Retail Availability in Fort Worth, Texas. Journal of Psychoactive Drugs, 2024, 56, 8-13.	1.0	1
77	Common street drug names for the anesthesiologist and pain physician. Regional Anesthesia and Pain Medicine, 2023, 48, 365-374.	1.1	0
78	Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom. Clinical Pharmacology and Therapeutics, 2023, 113, 1315-1325.	2.3	6
79	Diagnostic Ambiguities and Underuse of Clinical Assessment Tools: A Systematic Review of Case Reports on Kratom Addiction and Physical Dependence. Current Addiction Reports, 2023, 10, 282-292.	1.6	5
80	Evaluating health information provided to kratom consumers by good manufacturing practice-qualified vendors. Substance Abuse Treatment, Prevention, and Policy, 2023, 18, .	1.0	2
81	Kratom's Emergence and Persistence Within the US Polydrug Epidemic. Current Addiction Reports, 2023, 10, 262-271.	1.6	2